Zometa bone drug trial in post-menopausal women with breast cancer

[News]

Results from a latest large-scale clinical trial called Azure found that Novartis AG's bone drug Zometa extended survival in older breast cancer patients but failed to improve disease-free survival among younger women patients.

More... (http://www.news-medical.net/news/20110926/Zometa-bone-drug-trial-in-post-menopausal-women-with-breast-cancer.aspx)